Rezolute (NASDAQ:RZLT) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Rezolute (NASDAQ:RZLT) in a research report sent to investors on Thursday,Benzinga reports. They currently have a $14.00 price target on the stock.

Other research analysts have also issued reports about the stock. Wedbush restated an “outperform” rating and set a $112.00 target price on shares of Rezolute in a research report on Monday, November 4th. Guggenheim restated a “buy” rating on shares of Rezolute in a report on Monday. JMP Securities lifted their price objective on Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a report on Thursday. Finally, Craig Hallum upgraded Rezolute to a “strong-buy” rating in a research report on Tuesday, February 4th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $24.38.

Rezolute Price Performance

RZLT opened at $4.81 on Thursday. Rezolute has a 12 month low of $1.06 and a 12 month high of $6.19. The stock has a market capitalization of $278.69 million, a P/E ratio of -3.79 and a beta of 1.10. The business has a 50 day simple moving average of $4.88 and a 200-day simple moving average of $4.90.

Rezolute (NASDAQ:RZLT) last released its earnings results on Wednesday, February 12th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.11. Research analysts anticipate that Rezolute will post -0.99 EPS for the current year.

Insider Buying and Selling at Rezolute

In other Rezolute news, CFO Daron Evans purchased 9,000 shares of Rezolute stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $4.60 per share, with a total value of $41,400.00. Following the purchase, the chief financial officer now directly owns 140,900 shares in the company, valued at $648,140. This trade represents a 6.82 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 18.39% of the stock is owned by insiders.

Institutional Trading of Rezolute

A number of hedge funds have recently added to or reduced their stakes in the business. Walleye Capital LLC acquired a new stake in shares of Rezolute during the 4th quarter worth $2,408,000. Barclays PLC purchased a new position in Rezolute in the fourth quarter valued at approximately $314,000. ExodusPoint Capital Management LP acquired a new position in Rezolute during the fourth quarter valued at approximately $277,000. Geode Capital Management LLC lifted its position in Rezolute by 5.2% during the fourth quarter. Geode Capital Management LLC now owns 517,014 shares of the company’s stock valued at $2,535,000 after buying an additional 25,413 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in Rezolute by 62.1% during the fourth quarter. American Century Companies Inc. now owns 64,591 shares of the company’s stock worth $316,000 after buying an additional 24,742 shares during the period. 82.97% of the stock is owned by institutional investors and hedge funds.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.